Eli Lilly and Co

🇺🇸United States
Ownership
-
Employees
43K
Market Cap
$859.4B
Website
Introduction

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

theguardian.com
·

'Ozempic changed my life': do diabetes jabs boost the chances of conception?

Kathryn, diagnosed with gestational diabetes and struggling with weight, took Ozempic and unexpectedly conceived. Ozempic, a type 2 diabetes medicine, is not a fertility treatment but weight loss from GLP-1 drugs can improve fertility by restoring hormonal balance. A registry monitors pregnancies in women taking Wegovy, another GLP-1 drug. While weight loss is the main driver, some theorize GLP-1 drugs may interfere with oral contraceptives. Clinical trials are testing semaglutide in PCOS patients, suggesting potential fertility benefits. However, GLP-1 drugs are not recommended for conception due to safety concerns, and access remains limited.

Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes

Insulin efsitora alfa (efsitora) is a once-weekly basal insulin assessed for efficacy and safety in type 1 diabetes adults compared to insulin degludec (degludec). The study found efsitora non-inferior in HbA1c reduction but showed higher rates of severe hypoglycaemia, suggesting further evaluation of dose initiation and optimisation.
seekingalpha.com
·

Lilly gains FDA approval for lebrikizumab for atopic dermatitis

The U.S. FDA approves Eli Lilly's Ebglyss (lebrikizumab) for moderate-to-severe atopic dermatitis in patients 12 years and older. The IL-13 inhibitor is administered as a 250 mg/2 mL injection, with dosing every two weeks until week 16, followed by monthly maintenance. Approval was based on studies involving over 1,000 patients with uncontrolled eczema symptoms.
morningstar.com
·

Correction to Eli Lilly Gets FDA Approval for Eczema Treatment Article

Eli Lilly reports 38% of Ebglyss users achieved clear or almost-clear skin at 16 weeks, compared to 12% with placebo.
nature.com
·

Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer

R.A.S., M.S.T., C.Y., R.N., H.S.R., M.D., A.J.C., E.S.-R., J.C.B., C.O., K.K., A.D.E., C.V., N.W., K.S.A., A.S.C., C.F., C.I., A.T., J.T., K.Y., L.H., K.G., F.M.H., T.S., A.L.A., P.B., P.N., G.L.H., W.F.S., J.P., P.P., A.D.M., D.Y., L.J.v.V., N.M.H., L.J.E. report various institutional research funding, advisory roles, consultancy, honoraria, patents, and stock ownership.
dermatologytimes.com
·

FDA Approves Lebrikizumab-lbkz for Moderate to Severe Atopic Dermatitis

FDA approves Eli Lilly's lebrikizumab-lbkz (Ebglyss) for moderate to severe atopic dermatitis in patients aged 12+ who weigh at least 88 lbs (40 kg) and have not responded to topical therapies. Positive data from ADvocate 1, ADvocate 2, and ADhere studies support the approval, showing significant skin clearance and itch relief.
tipranks.com
·

Eli Lilly announces FDA approval of EBGLYSS

Eli Lilly announces FDA approval of EBGLYSS, an IL-13 inhibitor for moderate-to-severe atopic dermatitis in adults and children 12+ years old weighing at least 88 pounds, not well controlled by topical therapies.
medpagetoday.com
·

Lebrikizumab Wins FDA Approval for Eczema

FDA approves lebrikizumab (Ebglyss) for treating moderate-to-severe atopic dermatitis in adults and children 12+ years, with or without topical corticosteroids. The approval is supported by phase III ADvocate trials showing 38% of patients achieved clear or almost-clear skin at 16 weeks, compared to 12% with placebo. Common adverse events include eye and eyelid inflammation, injection site reactions, and shingles.

FDA approves lebrikizumab for atopic dermatitis in patients 12 years and older

FDA approves lebrikizumab (EBGLYSS) for moderate to severe atopic dermatitis in patients ≥12 years old, with a 250 mg / 2 mL monthly injection. Supported by ADVocate 1, 2, and ADhere trials, showing significant skin improvement in IGA scores. 77% maintained clear skin at 1 year post-treatment.
© Copyright 2024. All Rights Reserved by MedPath